-The Times of India   Maoist-affected districts across the country might have seen years of neglect by successive governments, but a new Central scheme - Integrated Action Plan (IAP) - under the UPA-II is fast filling up the 'critical gap' in those 'deficit zones' through taking up a number of development projects. As many as 67,072 basic infrastructure projects across 60 districts in nine states have been taken up at Rs 2,740...

When he drank poison on January 11, farmer Hargovind Harne’s run-down hut was bursting with freshly harvested paddy. Yet he was neck-deep in debt. Even the bottle of pesticide that he used to take his own life had been bought on credit, as the bill shows. His large stock of grain wasn’t the only puzzle in the 47-year-old’s suicide. Vidarbha is infamous for continuing suicides by cotton farmers but Harne grew food,...

 I first met Professor Suresh Tendulkar when I was a student at the Delhi School of Economics (DSE). He had also joined around the same time as a teacher at DSE. I have two vivid memories of him as a teacher. First, he would use the blackboard in a particular manner. He would start from one end of the board and write till the end of it. The board was...

The health ministry has erected bureaucratic hurdles against a bio-pesticide for mosquito control developed by Indian researchers, denying it entry into the public health programme while accepting similar imported products, scientists and entrepreneurs have said. The bio-pesticide was developed at the Vector Control Research Centre (VCRC) in Puducherry during the 1980s. It is a powder or spray formulation containing a bacterium called Bacillus thuringiensis that can kill the larvae of several...

India’s FTAs pip generic drugs production Lot More For Less     * Generic drugs from India play a major role as antiretroviral drugs across the developing world     * A 2010 study says 80% of the medicines used by donor-funded programmes to treat people with HIV were sourced from India     * It’s cut down treatment costs drastically, from $10,000 to $80     * Stronger IP regimes may hamper production of generics *** The right of...